APOLLOMICS INC (APLM)

KYG0411D1079 - Common Stock

0.1348  0 (-0.88%)

Fundamental Rating

1

Taking everything into account, APLM scores 1 out of 10 in our fundamental rating. APLM was compared to 573 industry peers in the Biotechnology industry. APLM may be in some trouble as it scores bad on both profitability and health. APLM is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year APLM has reported negative net income.
APLM had a negative operating cash flow in the past year.

1.2 Ratios

APLM has a worse Return On Assets (-311.63%) than 95.25% of its industry peers.
The Return On Equity of APLM (-418.59%) is worse than 78.35% of its industry peers.
Industry RankSector Rank
ROA -311.63%
ROE -418.59%
ROIC N/A
ROA(3y)-104.14%
ROA(5y)N/A
ROE(3y)-139.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

APLM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

APLM has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, APLM has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -25.03, we must say that APLM is in the distress zone and has some risk of bankruptcy.
APLM has a worse Altman-Z score (-25.03) than 88.73% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that APLM is not too dependend on debt financing.
APLM's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. APLM outperforms 47.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -25.03
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.95 indicates that APLM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.95, APLM is doing worse than 66.02% of the companies in the same industry.
A Quick Ratio of 2.95 indicates that APLM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.95, APLM is doing worse than 64.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.95

More info and screens

0

3. Growth

3.1 Past

APLM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -3757.18%.
EPS 1Y (TTM)-3757.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 3.52% on average over the next years.
APLM is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y52.55%
EPS Next 2Y16.83%
EPS Next 3Y3.52%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-23.3%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APLM. In the last year negative earnings were reported.
Also next year APLM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.83%
EPS Next 3Y3.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APLM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APOLLOMICS INC

NASDAQ:APLM (9/16/2024, 3:24:38 PM)

0.1348

0 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.82M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -311.63%
ROE -418.59%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.95
Quick Ratio 2.95
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-3757.18%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y52.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y